Discovery of I-0436650, a potent and selective SHP2 allosteric inhibitor for the treatment of RAS driven solid tumors

被引：0
|
作者：
Puca, F. [1 ]
Fodale, V. [1 ]
Randazzo, P. [2 ]
Fabbrini, D. [2 ]
Missineo, A. [1 ]
Bisbocci, M. [3 ]
Esposito, S. [4 ]
Nibbio, M. [4 ]
Amaudrut, J. [2 ]
Colaceci, F. [5 ]
Sasso, R. [5 ]
Scalabri, F. [1 ]
Loponte, S. [1 ]
Alli, C. [3 ]
Pucci, V. [4 ]
Montalbetti, C. [2 ]
Di Fabio, R. [2 ]
Petrocchi, A. [2 ]
Carugo, A. [1 ]
Toniatti, C. [1 ]
机构：
[1] IRBM SpA, Biol, Rome, Italy
[2] IRBM SpA, Small Mol R&D, Rome, Italy
[3] IRBM SpA, Translat Res, Rome, Italy
[4] IRBM SpA, Expt Pharmacol, Rome, Italy
[5] IRBM SpA, Vivo Pharmacol, Rome, Italy
来源：
EUROPEAN JOURNAL OF CANCER | 2022年 / 174卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
77
引用
收藏
页码：S26 / S26
页数：1
相关论文
共 50 条
  • [31] SHP2 inhibition as the backbone of targeted therapy combinations for the treatment of cancers driven by oncogenic mutations in the RAS pathway
    Smith, Jacqueline A.
    Singh, Mallika
    Nichols, Robert J.
    Koltun, Elena S.
    Yang, Yu C.
    Wildes, David P.
    Stahlhut, Carlos
    Lee, Dong
    Schulze, Chris J.
    Reyes, Denise
    Marquez, Abby
    Lee, Grace J.
    Li, Shaoling
    Marcireau, Christophe
    Debussche, Laurent
    Goldsmith, Mark A.
    Wang, Zhengping
    Gill, Adrian L.
    Kelsey, Steve M.
    CANCER RESEARCH, 2020, 80 (16)
  • [32] Structure-based design, synthesis and biological evaluation of aminopyrazines as highly potent, selective, and cellularly active allosteric SHP2 inhibitors
    Tang, Kai
    Zhao, Min
    Wu, Ya-Hong
    Wu, Qiong
    Wang, Shu
    Dong, Yu
    Yu, Bin
    Song, Yihui
    Liu, Hong-Min
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 230
  • [33] RAS mutation status predicts activity of the SHP2 inhibitor TNO155 in RAS-pathway driven fusion-negative rhabdomyosarcoma
    Baker, Andrew
    Odeniyide, Patience
    Skaist, Alyza
    Lisok, Alla
    Fertig, Elana
    Wang, Jiawan
    Pratilas, Christine
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [34] Maximizing the therapeutic potential of SHP2 inhibition with rational combination strategies in tumors driven by aberrant RAS-MAPK signaling
    Lee, Grace J.
    Stahlhut, Carlos
    Evans, James
    Reyes, Denise F.
    Lorenzana, Edward G.
    Li, Shaoling
    Koltun, Elena S.
    Lee, Dong
    Wang, Zhengping
    Nichols, Robert J.
    Smith, Jacqueline A.
    Singh, Mallika
    CANCER RESEARCH, 2019, 79 (13)
  • [35] Identification of a Novel, Potent, and Orally Bioavailable Guanidine-Based SHP2 Allosteric Inhibitor from Virtual Screening and Rational Structural Optimization for the Treatment of KRAS Mutant Cancers
    Hou, Qiangqiang
    Jiang, Wenhua
    Li, Wenqiang
    Huang, Chenyang
    Yang, Kexin
    Chen, Xiaoyu
    Huang, Mengchen
    Shu, Chengxia
    Luo, Guangmei
    Sun, Haopeng
    Chu, Qian
    Wu, Xiaoxing
    JOURNAL OF MEDICINAL CHEMISTRY, 2023, : 13646 - 13664
  • [36] Preliminary results from FLAGSHP-1: A Phase I dose escalation study of ERAS-601, a potent SHP2 inhibitor, in patients with previously treated advanced or metastatic solid tumors
    McKean, M.
    Barve, M.
    Hong, D.
    Parikh, A.
    Rosen, E.
    Yang, J.
    Picard, R.
    Yi, J.
    Brail, L.
    Vecchio, D.
    Meniawy, T.
    John, T.
    Wang, J.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S34 - S34
  • [37] Combining RAS(ON) G12C-selective inhibitor with SHP2 inhibition sensitises lung tumours to immune checkpoint blockade
    Anastasiou, Panayiotis
    Moore, Christopher
    Rana, Sareena
    Tomaschko, Mona
    Pillsbury, Claire E.
    de Castro, Andrea
    Boumelha, Jesse
    Mugarza, Edurne
    Trecesson, Sophie de Carne
    Mikolajczak, Ania
    Blaj, Cristina
    Goldstone, Robert
    Smith, Jacqueline A. M.
    Quintana, Elsa
    Molina-Arcas, Miriam
    Downward, Julian
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [38] ERAS-601, a potent allosteric inhibitor of SHP2, synergistically enhances the efficacy of sotorasib/adagrasib and cetuximab in NSCLC, CRC, and HNSCC tumor models
    Martin, Leenus
    Patel, Roopal
    Zhang, Jingchuan
    Nevarez, Robin
    Congdon, Taylor
    Brail, Les
    Shoemaker, Robert
    CANCER RESEARCH, 2022, 82 (12)
  • [39] Preliminary dose escalation results of ERAS-601 in combination with cetuximab in FLAGSHP-1: a phase I study of ERAS-601, a potent and selective SHP2 inhibitor, in patients with previously treated advanced or metastatic solid tumors
    McKean, Meredith
    Rosen, Ezra
    Barve, Minal
    Meniawy, Tarek
    Wang, Judy
    Hong, David S.
    Yang, Jennifer
    Li, Zhengrong
    Picard, Roxana
    Brail, Les
    Vecchio, Daniela
    John, Thomas
    Cohen, Ezra
    Obara, Gregory
    Parikh, Aparna
    CANCER RESEARCH, 2023, 83 (08)
  • [40] Discovery of a potent and subtype-selective TYK2 degrader based on an allosteric TYK2 inhibitor
    Kato, Jun-ya
    Korenaga, Shigeru
    Iwakura, Masaru
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2023, 79
12345